‡øëHŠÊ˜·³Ç

Since implementation, industry disclosure requirements have evolved into the published document that it is today through UK regulation, instructions from the European Federation of​​ Pharmaceutical Industry Associations (EFPIA), influences from the US, and decisions made by ‡øëHŠÊ˜·³Ç Board members.

• ​1958 ​First ‡øëHŠÊ˜·³Ç Code of Practice for the Pharmaceutical Industry
• ​1968 ​UK Medicines Act
• ​2006 ​‡øëHŠÊ˜·³Ç (UK) Code of Practice requires pharmaceutical companies to disclose their involvement with patient organisations including publishing a list of all patient organisations to which they provide financial support
• ​2007 ​EFPIA Patient Organisation Code agreed to come into operation on 1 July 2008
• ​2008 ​Revised ‡øëHŠÊ˜·³Ç Code of Practice
• ​2010 ​US Healthcare Reform
• ​2011 ​EFPIA updates Patient Organisation Code
• ​2011 ​Revised ‡øëHŠÊ˜·³Ç Code of Practice required pharmaceutical companies to disclose monetary value of support with a value of £250 or more (threshold removed in 2012)
• ​2012 ​The ‡øëHŠÊ˜·³Ç Code of Practice requires pharmaceutical companies to disclose payments to healthcare professionals in aggregate for the first time
• ​2012 ​The ‡øëHŠÊ˜·³Ç Code of Practice requires pharmaceutical companies to disclose grants and donations made to healthcare organisations on a per activity basis
• ​2013 ​US Sunshine Act established
• ​2013 ​EFPIA Disclosure Code agreed in June 2013
• ​2014 ​First US Sunshine Act report due​
• ​2014 ​Revised ‡øëHŠÊ˜·³Ç Code of Practice
• ​2015 ​Revised ‡øëHŠÊ˜·³Ç Code of Practice
• ​2016 ​Revised ‡øëHŠÊ˜·³Ç Code of Practice
• ​2016 ​First EFPIA Disclosures Report 2016
• ​2016 goes live on 30 June
  ​

Related content in this section:

• Disclosure UK
• Methodological notes by company and year
• About Disclosure UK
  • Definitions
  • History
  • I'm a pharmaceutical company
  • I'm a HCP or ORDM
  • I'm a HCO
  • I'm a member of the public
• Privacy Notice - Disclosure
• Resources